trending Market Intelligence /marketintelligence/en/news-insights/trending/mZpAO5NPdi_DKs0A5nwAvg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Pfizer reports improved results for breast cancer treatment in phase 3 trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Pfizer reports improved results for breast cancer treatment in phase 3 trial

Pfizer Inc.'s Ibrance in combination with letrozole showed improved progression-free survival in a phase 3 study for treating breast cancer.

Ibrance, in combination with an aromatase inhibitor, is approved in the U.S. as an initial endocrine-based therapy in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, or HER2-, advanced or metastatic breast cancer.

The U.S. Food and Drug Administration had granted regular approval for the indication in March based on data from the Paloma-2 phase 3 trial in which the combination achieved progression-free survival of 24.8 months versus14.5 months for placebo plus letrozole.

The latest data from the trial showed that the drug combination improved median progression-free survival by more than one year to 27.6 months compared to 14.5 months for placebo and letrozole.

The treatment reduced the risk of disease progression by 44%, with clinical benefit observed across all patient subgroups receiving the combination.

"The updated findings from Paloma-2 provide additional evidence to support the use of palbociclib with an aromatase inhibitor as a standard of care in the first-line setting for postmenopausal patients with hormone receptor-positive, HER2- metastatic breast cancer across all patient subgroups," Hope Rugo, lead author of the study, said in a news release.

Ibrance was the first CDK 4/6 inhibitor approved by any regulatory authority and now is approved in more than 75 countries.